Background People with type 2 diabetes are at risk of cognitive impairment and brain atrophy. We aimed to compare the eff ects on cognitive function and brain volume of intensive versus standard glycaemic control.
Introduction
People older than 70 years with type 2 diabetes have at least twice the likelihood of developing late-life cognitive impairment or dementia compared with those without type 2 diabetes. 1 The mechanisms underlying these cognitive disorders are increasingly thought to involve mixed pathology, with contributions from vascular, neurodegenerative, and neurovascular pro cesses. 2 Pathophysiological mechanisms that have been implicated include infl ammation, oxidative stress, energy imbalance, protein misfolding, glucocorticoid-mediated eff ects, and diff erences in genetic susceptibilities. 3, 4 On the basis of extensive published work on the causes, management, and prevention of diabetes, we took as a premise that early intervention with treatment strategies that improve glyceamic control could mitigate the adverse eff ects of type 2 diabetes on the brain. There are no clinical trials testing the eff ects of early intervention on brain outcomes in older people with type 2 diabetes. Targeting this risk group, we designed the Memory in Diabetes (MIND) substudy, embedded in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 5, 6 to test the primary hypothesis that at 40 months, people randomised to receive an intensive glycaemic treatment strategy targeting glycated haemoglobin A 1c (HbA 1c ) to less than 6·0% (42 mmol/mol) would have better cognitive function and a larger brain volume than people randomised to receive a standard strategy targeting HbA 1c to 7·0-7·9% (53-63 mmol/mol).
Methods
Participants ACCORD, described in detail elsewhere, 6 is a randomised, multicentre, double two-by-two factorial parallel treatment trial that tested the eff ect on cardiovascular disease events of treatment strategies to control blood glucose, blood pressure, and blood lipid concentrations. Participants targeted by ACCORD, which was done in 77 clinics in North America, were aged 45-79 years and had type 2 diabetes, high HbA 1c concentrations (>7·5%, >58 mmol/mol), and a high risk for cardiovascular disease events suggested by signifi cant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease. Key exclusion criteria were frequent or recent serious hypoglycaemic events, unwillingness to monitor glucose at home or inject insulin, body-mass index greater than 45 kg/m², serum creatinine level greater than 1·5 mg/dL (133 μmol/L), or other serious illness. 7 The MIND study design has been described elsewhere. 5 All ACCORD participants who entered randomisation were eligible for MIND if they were recruited between Aug 21, 2003 (34 months after the start of ACCORD), and Dec 16, 2005 , when the target sample size was reached. From this pool, we excluded participants younger than 55 years of age and those clinics (n=10) in the Veteran's Administration clinical centre network, because participants in this network were expected to be mainly men and we wanted to retain the overall sex balance. Additionally, 15 centres within the other six clinical centre networks declined to participate. The MIND participants were therefore drawn from 52 North American clinics in six of the seven clinical centre networks (webappen dix pp 1-4).
Within MIND, a subset of the participants from four clinical centre networks (28 clinics) were recruited for the MRI substudy. Initially we targeted only participants randomised to the glycaemic and blood pressure trials within ACCORD, but halfway through our study we extended recruitment to participants in the lipid trial to meet our sample size goals. We excluded participants with standard MRI exclusions. 8 To enhance retention, recruitment focused on participants living within 2 h of an MRI scanner.
The National Heart Lung and Blood Institute (NHLBI) sponsored ACCORD and an NHLBI review panel and the institutional review board or ethics committee at each participating centre approved the protocol. The National Institute on Aging (NIA) in collaboration with NHLBI sponsored the MIND trial, which was approved by the institutional review board of all participating institutions (webappendix pp 1-4). Participants signed separate informed consent for MIND.
Randomisation and masking
Each clinic was part of one of seven clinical centre networks and reported to a central coordinating centre. A computer at the central coordinating centre generated unique randomisation sequences for every clinical site and electronically verifi ed exclusion and inclusion criteria for every individual before assigning a treatment group. Clinic staff implemented the randomisation via secure access to the ACCORD trial website. Glycaemia trial treatment assignment was open label, and both clinic staff and patients were aware of the assigned glycaemic goal. The results of all ACCORD interim analyses were masked from study investigators.
Procedures
All ACCORD participants were randomly assigned to receive either intensive glycaemic treatment targeting HbA 1c to less than 6·0% (42 mmol/mol) or standard glycaemic treatment targeting HbA 1c to 7·0-7·9% (53-63 mmol/mol). Additionally, by use of the double two-by-two factorial design, participants in the bloodpressure trial were randomly assigned to receive either intensive blood pressure lowering treatment targeting systolic blood pressure to <120 mm Hg or standard treatment targeting systolic blood pressure to <140 mm Hg. Additionally, by use of the double two-by-two factorial design, participants in the lipid concentration trial were also randomly assigned to receive either fenofi brate or placebo, while good control of low-density lipoprotein cholesterol was maintained with simvastatin. 6 The ACCORD therapeutic intervention achieved the target HbA 1c with a range of strategies decided by the attending physician and tailored to the individual participant. All participants received diabetes education, glucose-monitoring equipment, and antidiabetic drugs. Participants in the intensive glycaemic group were started on two or more classes of drugs. Doses were intensifi ed or a new drug class was added monthly if HbA 1c con centrations were 6% (42 mmol/mol) or greater, or if more than 50% of premeal or postmeal capillary glucose readings were greater than 5·6 mmol/L (100 mg/dL). Standard glycaemic treatment was intensifi ed whenever HbA 1c was 8% (64 mmol/mol) or greater, or more than 50% of capillary glucose readings were greater than 7·8 mmol/L (140 mg/dL). Antihyperglycaemic drugs that promoted hypoglycaemia (ie, insulin or insulin secreta gogues) were reduced if HbA 1c was persistently below 7% (53 mmol/mol). All drug combinations from a standard formulary were permitted; specifi c drugs were reduced only for sideeff ects or contraindications. 9 The intensive intervention was stopped on Feb 6, 2008 , when an increased risk (hazard ratio 1·22, 95% CI 1·01-1·46) for mortality was reported; participants in that group were moved to standard glycaemic treatment. 7 MIND assessments continued in accordance with the original protocol. Here we report the glycaemia results, since this was the main intervention for which MIND was powered. Results for the other interventions will be reported elsewhere.
A cognitive test battery was administered at baseline and 20 months and 40 months after randomisation. The cognitive battery tested for verbal memory, processing speed, and executive function, which are typically impaired in people with type 2 diabetes. 10 Specifi c test selection, described in more detail elsewhere, 5 took into account the context of standardised testing in several clinics by trained lay staff , clinic time, and patient burden, as well as whether the tests had been previously used in studies of cognition and diabetes.
11 Our primary cognitive outcome was the number of correctly completed cells on the 40-month Digit Symbol Substitution Test (DSST), an omnibus test of psychomotor speed that also requires reasoning and working memory. 12 The results of this test have a normal distribution in the age-group of MIND participants, have been shown to change over time, are associated with diabetes and other cardiovascular outcomes, and might be less sensitive to educational level than those of other tests. 13 Secondary cognitive outcomes were memory, measured with the Rey Auditory Verbal Learning Test (RAVLT), and executive function, measured with the Stroop test. 5 The widely used MiniMental State Examination (MMSE) of general cognitive function was administered to allow comparisons with other studies. Quality control by the MIND coordinating centre (described elsewhere 5, 14 ) included tester certifi cation and recertifi cation, review of recorded test sessions, a tester helpdesk, and continual review of data entry and test-score distributions for unusual trends.
We chose total brain volume (TBV) as our primary MRI endpoint on the basis of evidence that diabetes can lead to mixed vascular and neurodegenerative changes, 15, 16 evidence of change in TBV over time, 17 and the relation of TBV to cognitive function and decline. Rates of whole brain atrophy are sensitive and powerful markers of disease progression in patients with Alzheimer's disease 18, 19 and diff er between people with and without diabetes; 20, 21 smaller values predict future cognitive disorders. 22 Our secondary MRI outcome was abnormal white matter (AWM) tissue volume, which is indicative of diff use and focal ischaemic, demyelinating, and infl ammatory processes leading to small vessel disease, and is associated with diabetes and impaired cognition. 21, 23 Brain MRI was done at baseline and at 40 months. The standardised MRI scan protocol, 5 used for all participants, was run on 1·5 T scanners and included a threedimensional fast spoiled gradient-echo T1-weighted (TR=21 ms, FA=30°, TE 8 ms), two-dimensional axial fast spin-echo fl uid attenuated inversion recovery (TR=8000 ms, TI=2000 ms, TE=100 ms), and protondensity/T2-weighted (TR=3200 ms, TE 1,2 =27 ms and 120 ms) sequences. Voxel size was 1·5 by 0·9 by 0·9 mm for the three-dimensional T1-weighted sequence and 3·0 by 0·9 by 0·9 mm for the two-dimensional sequences. The three-dimensional T1-weighted scans were used to study brain morphology, including volume, and the fast spin-echo scans were used to study pathological eff ects.
An operator at each centre ran the standardised magnetic resonance sequences that were programmed into the scanner and did not change during the study. MRI quality control accorded with the American College of Radiology's (ACR) MRI quality control programme. Digital images acquired at each centre were sent to the MRI quality control centre for in-house review on an asreceived basis. According to ACR phantom analyses, MRI scanner performance was stable across MRI sites and over the duration of our study.
Our image analysis was done with previously described methods, 24, 25 based on an automated multispectral computer algorithm that classifi es all supratentorial brain tissue into 92 volumetric anatomical regions of interest characterised as CSF, grey matter, or white matter. Grey and white matter were further characterised as normal and abnormal. AWM represented both diff use small-vessel disease and the hyperintensities that surround focal lesions. Grey matter and white matter regions of interest were summed to estimate TBV; TBV and CSF were summed to estimate intracranial volume (ICV), a measure of head size. Each participant's processed scan was reviewed by a trained individual who removed any scans verifi ed to have failed to reach a stable solution. ICV, an integrated measure of the stability of the MRI operator, scanning, and image analysis, did not signifi cantly change between baseline and follow-up examinations (baseline mean ICV 1132·34 cm³, follow-up mean ICV 1132·32 cm³; p=0·4651 by paired t test).
Statistical analyses
We estimated a sample size of 1400 participants per treatment group would, at 40 months, detect an 18% diff erence between groups (1 point on the DSST) with about 90% power, assuming a two-sided 0·05 type 1 error level, 15% dropout, and a 40-month DSST SD of 7·5, adjusted for baseline DSST.
We estimated an MRI sample size of 320 participants per group would detect a 20% diff erence in TBV (3·3 cm³) between groups at 40 months, with about 90% power, assuming a two-sided 0·05 type 1 error level, 15% dropout, and a TBV SD of 12·1, adjusted for baseline TVB. 17 We tested our cognitive function hypotheses with a mixed-eff ects model that incorporated information from both our 20-month and 40-month outcome measures. 26 In this model we assumed the probability of missing outcomes depended only on previous recorded outcomes or on factors in the model. Our basic model included terms for the glycaemia intervention and a visit eff ect, and an interaction term between the two. In a randomised trial the baseline covariates are independent of the random assignment, 27 so we could improve the effi ciency of our analysis by including in the model the baseline cognitive score and the factors used to stratify randomisation: second trial assignment (blood pressure or lipid), randomised group allocation within the bloodpressure and lipid trials respectively, clinical centre network, and history of cardiovascular disease.
Our MRI hypotheses were tested with an ANCOVA model that included ICV and factors used to stratify randomisation. We log transformed the highly skewed baseline and 40-month AWM data; we present the backtransformed estimates of treatment diff erences, which is the ratio of the treatment-specifi c geometric means. 28 We assessed robustness of the MRI results to missing 40-month data (including those due to death) in three multiple-imputation regression models that used baseline MRI information for imputation. In one model imputation was based on data pooled across treatment groups, a second based imputation on data from each treatment group separately, and a third assessed how much change in TBV would have been needed in the participants receiving intensive glycaemic treatment for whom 40-month data were missing for the treatment comparison to no longer be signifi cant. Following the fi nding that participants in the intensive-treatment group gained more weight than those in the standardtreatment group, 7 we did post-hoc exploratory analyses for treatment diff erences in oedematous disorders (pretibial oedema, worsened ankle swelling, coronary heart failure, pulmonary oedema, new or worsened shortness of breath, or nocturia), or whether weight gain was associated with TBV and AWM within treatment groups. We did prespecifi ed subgroup analyses for sex, history of cardiovascular disease, treatment group in the lipid or blood pressure trials, and clinical centre network. Posthoc exploratory subgroup analyses included baseline age (<60, 60-69, ≥70 years), 29 duration of diabetes (<5, 6-10, 11-15, ≥16 years), 14, 30 and DSST (<47, 47-59, ≥60). 31 We tested all hypotheses at the two-sided 0·05 level. We did all statistical analyses with S-Plus 8.0 or SAS 9.2. This study is registered with ClinicalTrials.gov, number NCT00182910.
Role of the funding source
Staff from the NHLBI (ACCORD sponsor) served on the executive and steering committees that made decisions on study design, methods, and data collection. The NIA (MIND sponsor) had no role in the study design, in the collection, analysis, and interpretation of the data, in writing the report, or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of the 2957 (99%) of 2977 MIND participants with a baseline DSST assessment (fi gure 1), 2794 (94%) had at least 20-month or 40-month follow-up and were included in our fi nal analysis. Completion rates for the other tests were similar to those for the DSST. Participants with missing follow-up data were older, had a higher systolic blood pressure, and a lower baseline DSST but were otherwise similar to those with complete data.
Our trial participants had a mean age of 62·5 years (5·8) and were similar to the overall eligible ACCORD sample (webappendix p 6) and the treatment groups were similar to each other (table 1). The substantial separation achieved in median HbA 1C between the intensivetreatment (6·6%; 49 mmol/mol) and standard-treatment (7·5%; 58 mmol/mol) groups was similar to that in the main ACCORD trial. When the intensive glycaemic intervention was stopped and participants in that group †Baseline mean is the overall mean for both groups combined as measured before randomisation. This value is used to obtain the least squares means estimates at follow-up. Models are adjusted for baseline cognitive score and the factors used to stratify randomisation: second trial assignment (blood pressure or lipid concentration), randomly assigned group allocation within the blood pressure and lipid concentration trials, clinical centre network, and history of cardiovascular disease. ‡Pre-specified co-primary outcomes. participants in the intensive-treatment group of the cognitive substudy had received treatment for a median of 39 months (IQR 34-40) and those in the MRI substudy had received treatment for 35 months (31-40). Mortality in the MIND participants in the intensive-treatment group (n=47) versus the standard-treatment group (n=39; hazard ratio 1·27, 95% CI 0·83-1·93) was consistent with that recorded overall in ACCORD. DSST scores signifi cantly declined in both treatment groups (table 2) . At 20 months, the between-group diff erence in DSST scores approached statistical signifi cance, but at 40 months the diff erence was attenuated and not signifi cant (table 2) . There were no consistent subgroup diff erences by intervention (webappendix p 9).
During follow-up, there was a small increase in mean RAVLT scores within both groups, but no signifi cant diff erence between groups (table 2). Performance on the Stroop test improved slightly in the intensive-treatment group and declined slightly in the standard-treatment group, but there was no diff erence between treatments (table 2). There were no consistent subgroup diff erences by intervention for either cognitive test (webappendix pp [10] [11] .
Of the 632 participants recruited into our MRI substudy, 614 (97%) participants (fi gure 2) had a successful baseline MRI and were similar for baseline characteristics to all other MIND participants (webappendix p 7) and between treatment groups (table 3) At 40 months, the intensive-treatment group had signifi cantly greater TBV compared with the standardtreatment group (table 2) . Although TBV declined in both groups, the TBV of the intensive-treatment group declined less: 13·0 cm³ (0·41% per year) compared with 17·7 cm³ (0·57% per year) in the standard-treatment group. Our imputation-based sensitivity analyses showed similar results. The participants in the intensive group who missed a 40-month MRI would have to experience, on average, a greater than 22·0 cm³ decline (73% increase over the change in those with recorded data) for the results to become non-signifi cant. The eff ect on TBV of the interventions did not diff er by subgroup (previous cardiovascular disease p=0·1508, sex p=0·6336, clinical centre network p=0·6509, diabetes duration p=0·7167, age p=0·4824, and DSST p=0·4650).
At 40 months, there was signifi cantly more AWM in the intensive-treatment group (geometric mean 1·89 cm³; 95% CI 1·78-2·00) compared with the standardtreatment group (1·71 cm³, 1·62-1·80; ratio of geometric means 1·10 cm³, 1·02-1·19; p=0·0156). However, this eff ect seemed to be restricted to participants younger than 60 years (interaction between the glycaemia intervention and baseline age p=0·0045; ratio of intensive to standard geometric means for patients younger than There were no other treatment diff erences across baseline subgroups (previous cardiovascular disease p=0·35, sex p=0·82, clinical centre network p=0·3401, diabetes duration p=0·7496, and DSST p=0·8073). There was no evidence that measures of peripheral oedema or weight gain could explain the diff erences in TBV or AWM between treatment groups.
Discussion
To our knowledge, ACCORD MIND is the fi rst randomised study in older people with type 2 diabetes to test the eff ect of intensive compared with standard glycaemic lowering strategies on cognitive domains and on structural changes in the brain (panel). Overall, there is no evidence in this patient group, which had longstanding type 2 diabetes, a high risk of cardiovascular disease, and mean age of 62 years, that an intensive glycaemic treatment strategy provides benefi t to cognitive function. There was a signifi cant but small diff erence in TBV favouring the intensive strategy. However, this diff erence does not support the use of intensive treatment to reduce brain atrophy in view of the eff ects of this intervention in the main ACCORD trial: raised mortality, no overall benefi t on cardiovascular disease events, an increase in hypoglycaemic events, and weight gain. In the 30% of ACCORD participants who entered the MIND substudy, the separation in HbA 1c concentrations, and diff erences in mortality rates between the treatment strategy groups, were similar to those in the main trial. There was reasonable balance of baseline characteristics between treatment groups. Adherence to the cognitive assessment protocol and retention of patients in the study was high, minimising the likelihood of bias. The cognitive battery was successfully administered in a standardised manner in many geographically and demographically diverse clinics; fewer 40-month DSST assessments than expected were missing (11% [n=333] actual vs 15% expected), and these were distributed similarly across the treatment groups (11% [n=165] intensive vs 11% [n=168] standard). Our overall conclusions did not change with diff erent assumptions about the missing 40-month scans.
Several factors might have attenuated treatment diff erences in cognitive scores. Not all participants completed 40 months on intensive treatment, but most had at least 34 months. Methodological factors, such as practice eff ects, might contribute, but these eff ects should be similar in both treatment groups. The tests might not have measured appropriate functions, but those functions have been repeatedly shown to be aff ected in people with type 2 diabetes 10 and the tests are appropriate for a large-scale heterogeneous study population. For the deaths to have aff ected our conclusion in favour of intensive treatment, substantially higher follow-up cognitive scores would have been needed from the 47 people who died in the intensive group than from the 39 in the standard group. We think this would be unlikely, because it assumes that those on intensive therapy who died would have experienced a greater treatment-group eff ect than those who survived.
Several other explanations are possible. High patient motivation and the optimum diabetes care provided to all participants might have brought glucose into suffi cient control to have mitigated some cerebral pathology caused by type 2 diabetes. 3 Optimum treatment has been raised as a reason for the null eff ect on cognition in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications trial. 33 Age might also be a factor in that treatment diff erences might have been more apparent if the intervention had been given during a period when participants were experiencing more rapid decline in cognition. 35 It has been suggested that up to age 70 years there is little measurable cognitive decline in people with type 2 diabetes, although after that the rates of decline begin to diverge between those who remain cognitively stable and those who will develop mild cognitive impairment or Alzheimer's disease. It is also possible that an intensive treatment strategy does not improve outcomes in the group of patients targeted by ACCORD.
The annualised decline in TBV (3·9 cm³) in the intensive-treatment group is 26% less than that in the standard-treatment group (5·31 cm³). From another perspective, a study of people with a mean age of 76 years recorded that TBV of cognitively stable people declined 0·4% per year compared with 0·8% per year in those who converted to mild cognitive impairment or dementia. 36 This is compared with an annual decline of 0·41% in the intensive-treatment group and 0·57% in the standard-treatment group in ACCORD MIND. The increase in AWM volume in participants younger than 60 years in the intensive group needs further study. We did not identify evidence that major factors such as oedema or weight gain aff ected the results, although another unknown or unmeasured side-eff ect might have resulted in TBV treatment diff erences. Taking the cognitive and MRI fi ndings together, it is reasonable to postulate that, in this age-group, structural changes in the brain happen before cognitive changes and that over time cognitive diff erences between treatment groups would emerge. With additional ongoing follow-up of the cohort, we will be able to establish whether, above the benefi ts of standard therapy, the diff erent treatment strategies resulted in diff erent rates of cognitive change. At present, there is little evidence to quantify the clinical eff ect of the recorded treatment diff erences. We feel it is reasonable to suggest that a larger decline in brain capacity will lead to earlier loss of function and possibly dementia-the MIND participants at an approximate mean age of 62 years are already experiencing an annual decline of TBV in the range reported for people 15 years older, 36 when the incidence of dementia increases logarithmically. Furthermore, there are few data quantifying the progression of brain changes in people with type 2 diabetes who are similar in age to MIND participants, and little is known about the functional eff ects of accumulating small decrements in brain structure and function or about the determinants of who, in a general population, will go on to develop dementia. Most data on people with diabetes describe patterns in younger people with type 1 diabetes, 37 or in cohorts that are at least 10 years older. 1 However, MIND participants are in the crucial age range when disease processes in the brain begin to accelerate, eventually leading to double the risk of dementia in people with type 2 diabetes compared with people without this disorder. Gaps in our knowledge of this transition phase clearly need to be fi lled if we are to design eff ective prevention strategies.
Cognitive function aff ects the ability of patients to follow complex disease management protocols, and impaired cognition predicts cardiovascular disease and severe hypoglycaemic events. 38 Early prevention strategies to reduce the risk of cognitive impairment are needed because, as the longevity of patients with diabetes increases, so too does the number reaching an age at which cognitive disorders become clinically apparent. Optimum treatment strategies for brain health in older people with type 2 diabetes are needed and should be assessed in the context of a comprehensive assessment of therapeutic strategies to manage type 2 diabetes and its consequences.
